VP, Discovery Bioscience
Dr. Peter Fekkes is a seasoned drug hunter with 18 years of industry experience in company environments ranging from major global Pharma to well-established biotech to start-ups. At FogPharma, Dr. Fekkes is responsible for building and managing the product engine that supports the efficient progression of hyperstabilized alpha-helical peptide hits to leads to clinical molecules, with an emphasis on rigorous elucidation of biochemical, biophysical, and structural mechanism-of-action; and on the development of highly multiplexed technologies for the optimization of target affinity, cell penetration, and target engagement in cells. To this role Dr. Fekkes brings an exceptional track record of success, plus depth and breadth of experience in developing and implementing strategies to identify potent target effectors against a broad range of targets and drug modalities.
Prior to joining FogPharma, Dr. Fekkes held roles of increasing responsibility at Novartis, H3 Biomedicine, and HotSpot Therapeutics. Most recently, he headed the New Target Platform at HotSpot Therapeutics, where he applied artificial intelligence approaches to the identification of targets with suitable pockets that are functionally involved in allosteric regulation. Dr. Fekkes also guided the drug discovery efforts on the early target portfolio. Before that, he successfully built the Biochemistry and Lead Discovery Group at H3 Biomedicine and supported the entry of molecules into the clinic for three different programs, all starting form a well-defined mode-of-action hypothesis. A signature accomplishment at H3 was the pivotal role he played in elucidating the mode of action of a novel spliceosome modulator now in Phase I clinical development.
Dr. Fekkes holds a Ph.D. in Molecular Biology from the University of Groningen, The Netherlands, and completed a postdoctoral fellowship at the University of California, San Diego.